VERSATILE-003: a phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma

Category Primary study
ConferenceAsco meeting abstracts
Year 2025
This article has no abstract
Epistemonikos ID: 411813e6e498dc2bad490c42169059ec03707ed7
First added on: May 16, 2026